Gedalia built TrufaMED around physician-led protocols, Joint Commission accreditation, and a standard of care usually reserved for hospital systems
On Friday, the company released the latest data from its Phase II trial of their oral drug NG101
By tailoring its offering for patients with side effects or an aversion to needles, Gaston Kroub, a patent lawyer in New York, said Hims is positioning the oral product as another personalized option, widening the scope of personalization under the FDAs framework
95% CI, 1.131.47
Barman, P., Joshi, S., Sharma, S., Simran Preet, Sharma, S., & Saini, A
However, additive side effects like nausea or mood changes can occur